Track .

Securities offered to employees pursuant to employee benefit plans These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient  amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers' information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment plan will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.

SPRINGFIELD, Mass. Q4 2020 Report - financial statement for the months October - December . Feb. 2021. (Common Stock)

Thursday, September 17, 2020 For the first quarter 2020, KindredBio reported net product revenues of $0.6 million and a net loss of $22.8 … In 2014, Steve started Kindred Ventures as a small seed fund with his personal capital, a dozen prior angel investments, and passion to help other founders.

EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Transparency. The kindred way. The Investor Relations website contains information about Kindred Biosciences, Inc.'s business for stockholders, potential investors, and financial analysts. 06.

Nov. 2020. Investor calendar. Kindred Biosciences Announces First Quarter 2020 Financial Results

Tuesday, September 15, 2020 from 3:30 PM to 3:50 PM EDT (Common Stock)

Tuesday, September 15, 2020 from 3:30 PM to 3:50 PM EDT Kindred Biosciences Inc at Cantor Virtual Global Healthcare Conference© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth Conference Kindred Biosciences Inc at Lake Street Best Ideas Growth ConferenceThese forward-looking statements are based on our current expectations. Kindred Biosciences Inc at H. C. Wainwright 22nd Annual Global Investment ConferenceReport of unscheduled material events or corporate eventKindred Biosciences Announces Second Quarter 2020 Financial ResultsKindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal AntibodySEC Filings